Home › Research › Treatments
Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions
Ozioma C. Okonkwo, Mónica Rivera Mindt, Michael Walter Weiner, for the Alzheimer's Disease Neuroimaging Initiative. Alzheimer s & Dementia, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging.The earliest origins of ADNI lie in the groundbreaking discovery that antibodies targeting amyloid can remove amyloid beta (Aβ) plaques, sparking the advent of immunotherapy for Alzheimer's disease (AD). 1 At the same time, the importance of imaging and fluid biomarkers, particularly cerebrospinal fluid (CSF), in AD diagnosis gained recognition.ADNI was established in 2004 to validate and optimize biomarkers for AD clinical trials and freely share all the generated data with the scientific community without any restrictions.Since then, ADNI has evolved through five sequential phases incorporating advancements in the field and contributing to significant breakthroughs such as standardizing and validating Aβ and tau positron emission tomography (PET) imaging and CSF biomarkers.2-4 Moreover, ADNI data informed the design of clinical trials for aducanumab, 5 lecanemab, 6 donanemab, 7 solanezumab, 8 verubecestat, 9 crenezumab, 10 and gantenerumab, 11 facilitating the introduction of disease-modifying treatments into clinical practice.ADNI's open data sharing has led to over 6000 peer-reviewed publications, further highlighting the impact of the study.Furthermore, ADNI's approach to conducting longitudinal observational studies and openly sharing data served as a model for similar initiatives globally, leading to the creation of consortia like the Parkinson's Progression Markers Initiative (PPMI), 12 Japanese ADNI, 13 European ADNI, 14 Korean Brain Aging Study (KBASE), 15,16 China ADNI, 17 and South American initiatives.18 The following projects were also modeled on ADNI: the Dominantly Inherited Alzheimer Network (DIAN) studies, 19 Alzheimer's Disease Research Center Consortium for Clarity in Alzheimer's Disease and Related Dementias Research Through Imaging (CLARiTI), 20 Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), 21 Australian Imaging Biomarker & Lifestyle Flagship Study of Ageing (AIBL), 22 Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects Longitudinal Frontotemporal Lobar Degeneration (ALLFTD), 23 Diverse Vascular Contributions to Cognitive Impairment and Dementia (VCID), 24 and Biomarkers for Vascular Contr
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. ADNI was established to validate and optimize biomarkers for Alzheimer's clinical trials and shares its data openly, contributing to standardized Aβ and tau PET imaging and CSF biomarkers. ADNI data informed the design of trials for several drugs including aducanumab, lecanemab and donanemab, helping to bring disease-modifying treatments into clinical practice.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Okonkwo, O. C., Mindt, M. R., Weiner, M. W., & Alzheimer's Disease Neuroimaging Initiative. (2025). Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14186
Vancouver
Okonkwo OC, Mindt MR, Weiner MW, Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14186. PMID: 39760440.
BibTeX
@article{okonkwo2025-39760440,
author = {Okonkwo, Ozioma C. and Mindt, Mónica Rivera and Weiner, Michael Walter and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.14186},
pmid = {39760440},
url = {https://doi.org/10.1002/alz.14186}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging.The earliest origins of ADNI lie in the groundbreakin
Why it matters
ADNI was established to validate and optimize biomarkers for Alzheimer's clinical trials and shares its data openly, contributing to standardized Aβ and tau PET imaging and CSF biomarkers. ADNI data informed the design of trials for several drugs including aducanumab, lecanemab and donanemab, helping to bring disease-modifying treatments into clinical practice.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 51/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39760440) |
| Free to read | 2 / 2 | Free to read |
| Points | 49 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100. |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.